New celiac diagnostic passes first safety test in humans
NCT ID NCT07063823
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 29 times
Summary
This early-stage study tested a single oral dose of HB-2121 in 18 adults (some with celiac disease, some healthy) to see if it is safe and how the body processes it. Participants were monitored for 30 days with clinic visits and daily symptom questionnaires. The goal was to check for side effects and measure drug levels in the blood, not to treat the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Stanford University
Stanford, California, 94305, United States
Conditions
Explore the condition pages connected to this study.